Intelligence Platform

Patents

Browse 126 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11261444

Organic compositions to treat EPAS1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11214802

RNAi agents for inhibiting expression of alpha-ENaC and methods of use

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11214801

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208662

RNAi inhibition of alpha-ENaC expression

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11203756

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11180529

Alpha-v beta-6 integrin ligands and uses thereof

Arrowhead Pharmaceuticals, Inc. · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174481

Targeting ligands

Arrowhead Pharmaceuticals, Inc. · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11091761

Organic compositions to treat HSF1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11078227

5′-cyclo-phosphonate modified nucleotides

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066667

Organic compositions to treat APOC3-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10995335

RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), a

Arrowhead Pharmaceuticals, Inc. · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10927373

Compositions and methods for inhibiting gene expression of Hif2alpha

Arrowhead Pharmaceuticals, Inc. · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10858658

Compositions and methods for inhibiting gene expression of factor XII

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10806750

RNAi therapy for hepatitis B virus infection

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10780108

RNAi agents for Hepatitis B virus infection

Arrowhead Pharmaceuticals, Inc. · Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10619160

Compositions and methods for inhibiting expression of RRM2 genes

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10597657

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10590416

RNAi agents for inhibiting expression of alpha-ENaC and methods of use

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10550391

Organic compositions to treat beta-ENaC-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10544418

RNAi inhibition of alpha-ENaC expression

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10538765

Organic compositions to treat EPAS1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10450565

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10329563

Organic compositions to treat HSF1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10316316

Compositions for targeted delivery of siRNA

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted